


Diuretics and other masking agents




Diuretics:


Increase in diuresis: excretion of electrolytes, hydrophilic and water-soluble compounds. Pharmacological effect in the case of edema / hypertension.

Kidney function:

- maintaining the homeostatic balance of electrolytes and water.
- excretion of water-soluble metabolites.
- Functional unit: *nephron*.




Diuretics (Masking agents)




Osmotic diuretics: action on proximal convoluted tubule.

Polyalcohols/sugars:


MANNITOL




SORBITOL




ISOSORBIDE




GLUCOSE



(UREA): pK_A 15.73, water solubility (25°C) 120 g / 100 g



Diuretics




Carbonic anhydrase inhibitors: action on proximal / distal convoluted tubules. Urine alkalinization. Blood acidosis.




Sulphonamides : anti-glaucoma


ACETAZOLAMIDE, pK_A 6.93



METAZOLAMIDE, pK_A 6.93




Diuretics




Thiazides: low effect as carbonic anhydrase inhibitors. The main mechanism of action involves the inhibition of Na^+/Cl^- co-transportation system in distal convoluted tubule (saluretics). Tox: hypokalemia.

Benzothiadiazines



CHLORTIAZIDE


BENDROFLUMETHIAZIDE




| Name | HYDROCHLOROTHIAZIDE |
|-------------------|---|
| Structure | |
| Systematic name | 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide |
| Formula | $\text{C}_7\text{H}_8\text{ClN}_3\text{O}_4\text{S}_2$ |
| MW | 297.739 |
| Monoisotopic mass | 296.964474846 |
| Mp | 273-275°C |
| H bond acceptors | 7 |
| H bond donors | 4 |
| Acid pKa | 9.09 (primary sulphonamide); 9.83 (secondary sulphonamide); 11.31 (aniline) |
| Basic pKa | -- |
| ACD Log D pH 5.5 | -0.07 |
| ACD Log D pH 7.4 | -0.09 |
| Solubility | water |
| LD50 | 3080 mg/Kg mouse p.o. |
| Therapeutic cat | diuretic |
| ATC | C03AA03 C CARDIOVASCULAR SYSTEM C03 DIURETICS C03A LOW-CEILING DIURETICS, THIAZIDES C03AA Thiazides, plain |
| C03AB03 | hydrochlorothiazide and potassium |
| C03EA01 | hydrochlorothiazide and potassium-sparing agents |
| C03AX01 | hydrochlorothiazide, combinations |
| Receptors | nephron electroneutral Na^+/Cl^- co-transporter |

| Nomi commerciali (IT) | |
|---|----------------------------------|
| ESIDREX | A, RR, compresse |
| ACCURETIC, ACEDIUR, ACEPLUS, ACEQUIDE, ACESISTEM, ALDACTAZIDE, AVEDAR, BENAZEPRIL IDR., BIFRIZIDE, BLOPRESID, CAPTOPRIL IDR., CIBADREX, CLORISIP, COAPROVEL, COMBISARTAN, CONDIUREN, CORXIL, COTAREG, ELEKTRA, ENALAPRIL IDR., ENEFIN, ENSOR, ENULID, ESIDREX, FEMIPRES, FORZAAR, FOSICOMBI, FOSINOPRIL IDR., GENTIPRESS, HERZAPLUS, HIZAAR, IDROQUARK, INIBACE, INITISS, IVREX, KARVEZIDE, KRUPPLUS, LISINOPRIL IDR., LOBIDIUR, LODIOZ, LOSARTAN IDR., LOSAZID, LOZID, MICARDIPLUS, MODURETIC, NALAPRES, NEOLOTAN, NEOPREX, NOBIZIDE, NORAZIDE, OLMEGAN, OLPREZIDE, PLAUNAZIDE, PRECTIAZIDE, PRINZIDE, PRITORPLUS, QUINALAPRIL IDR., QUINAZIDE, RAMIPRIL IDR., RATAACAND, SINERTEC, SPIRIDAZIDE, TENSADIUR, TENSOZIDE, TIARTAN, TRIATEC HCT, UNIPRIL DIUR, VASORETIC, ZANTIPRIDE, ZESTORETIC, ZINADIUR | associazione con antiipertensivi |

Diuretics






Thiazides:




Benzothiadiazines SAR


EW in 6 is critical. Long duration of action for high lipophilicity. The 7-sulphonamide group is indispensable. The introduction of a lipophilic group in 3 (or on the N 2) increases the activity.



CHLORTIAZIDE




HYDROCHLORTIAZIDE



BENDROFLUMETHIAZIDE


Diuretics



Quinazolinones, phthalimides, indolines: same mechanism of thiazides, long duration of action.


Quinazolinones

QUINETHAZONE




Phthalimides:

CHLORTHALIDONE



Indolines:

INDAPAMIDE




Diuretics




High-ceiling diuretics: Henle's loop $\text{Na}^+/\text{K}^+ / 2\text{Cl}^-$ transportation. Short duration of action. Strong saluretic: -25% of plasmatic Na^+ . Risk of hypokalemia.

Anthranilic acid derivatives

Di-acidic compounds: **FUROSEMIDE**




BUMETANIDE: 4 h action



| | |
|-------------------|--|
| Name | FUROSEMIDE |
| Structure | |
| Systematic name | 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid |
| Formula | $\text{C}_{12}\text{H}_{11}\text{ClN}_2\text{O}_5\text{S}$ |
| MW | 330.744 |
| Monoisotopic mass | 330.007719869 |
| Mp | 205°C |
| H bond acceptors | 7 |
| H bond donors | 4 |
| Acid pKa | 4.25 (carboxyl); 9.83 (sulphonamide) |
| Basic pKa | -- |
| ACD Log D pH 5.5 | 0.69 |
| ACD Log D pH 7.4 | -0.03 |
| Solubility | water 0.006 mg/mL, methanol, basic soln. |
| LD50 | 2600 mg/Kg rat p.o. |
| Therapeutic cat | diuretic |
| ATC | C03CA01 C CARDIOVASCULAR SYSTEM C03 DIURETICS C03C HIGH-CEILING DIURETICS C03CA Sulfonamides, plain |
| Receptors | Henle's loop $\text{Na}^+/\text{K}^+/\text{Cl}^-$ transportation |

| | |
|---------------------------|--------------------------------------|
| Nomi commerciali (IT) | |
| DIUREN, FUROSEMIDE, LASIX | A, RR, compresse, gocce, iniettabili |


Diuretics



High-ceiling diuretics: Henle's loop $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ transportation. Action on sulphidrylic enzymes for solute re-absorption.


Phenoxyacetic acid derivatives

ETHACRYNIC ACID




Tetrazoles: AZOSEMIDE

Tetrazole: carboxylic bioisostere




Diuretics



Potassium-sparing diuretics: Mineral-corticoid antagonists.


Anti-hormone diuretics


SPIRONOLACTONE: competitive ALDOSTERONE antagonist




It acts against Na^+/Cl^- reabsorption and favours K^+ retention.

Metabolized to **CANRENONE**




| | |
|---|---|
| Name | SPIRONOLACTONE |
| Structure |  |
| Systematic name | [[7R,8R,9S,10R,13S,14S,17R]-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate |
| Formula | $\text{C}_{24}\text{H}_{32}\text{O}_4\text{S}$ |
| MW | 416.573 |
| Monoisotopic mass | 416.202130202 |
| Mp | 135°C |
| H bond acceptors | 4 |
| H bond donors | 0 |
| Acid pKa | -- |
| Basic pKa | -- |
| ACD Log D pH 5.5 | 3.12 |
| ACD Log D pH 7.4 | 3.12 |
| Solubility | DMSO, ethanol |
| LD50 | 260 mg/Kg rat i.p. |
| Therapeutic cat | diuretic |
| ATC | C03DA01 C CARDIOVASCULAR SYSTEM C03 DIURETICS C03D POTASSIUM-SPARING AGENTS C03DA Aldosterone antagonists |
| Receptors | Aldosterone |
| Nomi commerciali (IT) | |
| ALDACTONE, PRILACTONE, SPIROLANG, URACTONE e associazioni | A, RR, compresse, capsule |

Diuretics



Potassium-sparing diuretics: Act inhibiting sodium reabsorption in the late distal convoluted tubules.





Pteridines




TRIAMTERENE: Basic compound ($pK_{A \text{ aromatic guanidine}}: 3.11$) blocks the epithelial sodium channel on the lumen side of the kidney collecting tubule

Aminopirazines.

AMILORIDE (pK_{A} s: 1.44_{arom} 3.29_{guanid})




Diuretics



Vasopressin receptor antagonists: non-peptide inhibitor of antidiuretic hormone.

Benzazepines.

TOLVAPTAN: V2 receptor. used to treat hyponatremia occurring with heart failure



CONIVAPTAN: V1 and V2 receptors

